Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer
ASCO 2016 – Lung Cancer
Read More ›
Treating Gastric Cancer by Targeting Notch and wnt-Beta-Catenin Cancer Stem-Cell Pathways
ASCO 2016 – GI
An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer.
Read More ›
BBI608/FOLFIRI ± Bevacizumab in Advanced Colorectal Cancer
ASCO 2016 – GI
Read More ›
NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer
ASCO 2016 – GI
Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer.
Read More ›
STEAM—Sequential versus Concurrent FOLFOXIRI/Bevacizumab in Metastatic Colorectal Cancer
ASCO 2016 – GI
Read More ›
Avelumab in Advanced Gastric or Gastroesophageal Cancer
ASCO 2016 – GI
Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression.
Read More ›
Nivolumab Monotherapy in Advanced Gastroesophageal or Gastric Cancer
ASCO 2016 – GI
Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer.
Read More ›
Pembrolizumab in PD-L1+ Advanced Esophageal Carcinoma
ASCO 2016 – GI
Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma.
Read More ›
The Role of the mTOR Pathway in Cancer Stem Cells in Esophageal Cancer
ASCO 2016 – GI
Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer.
Read More ›
Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
ASCO 2016 – GI
Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Read More ›
Page 122 of 147
119
120
121
122
123
124
125
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us